Skip to content

Medical emergency? What to do

Genetic Variation Helps to Understand Predisposition to Schizophrenia

3-RXPublished August 9, 20075 min read

Key points

  • Scientists have provided new insight into how a gene is related to schizophrenia.
  • The study was selected as a “Paper of the Week” by the journal’s editors, meaning that it belongs to the top one percent of papers reviewed in significance and overall importance.
  • In 2006, Law and colleagues found that one of these DNA variations is associated with increased expression of a novel type of Neuregulin 1 called type 4 – one of the six known types of Neuregulin 1 proteins – in the brains of patients with schizophrenia.
  • “Since the Neuregulin 1 protein plays a key role in brain development and is more abundant in fetal brains, DNA changes that alter the expression of this protein may contribute to schizophrenia by modifying the development and wiring of the brain,” Law says.

Scientists have provided new insight into how a gene is related to schizophrenia. In a study to be published in the August 17 issue of the Journal of Biological Chemistry, Amanda J. Law, Medical Research Council Fellow and Associate Professor at the University of Oxford, United Kingdom, and Visiting Scientist at the National Institutes of Health (NIH), along with colleagues at NIH describe for the first time a genetic variation that causes a gene to be overexpressed in the human brain. These results may provide a new way to design better drugs to treat schizophrenia.

“Although the exact causes of schizophrenia are yet to be determined, scientists agree that the disease is in part due to genetic variations,” Law says. “These variations are not simple to understand because they don’t directly disturb the function of proteins. In our study, we identified some clues as to what goes wrong with one of these DNA variations.”

The study was selected as a “Paper of the Week” by the journal’s editors, meaning that it belongs to the top one percent of papers reviewed in significance and overall importance.

Scientists originally found in an Icelandic population that genetic variations in a DNA sequence close to a gene that produces a protein called Neuregulin 1 were associated with schizophrenia, but how the Neuregulin 1 gene was affected remained unknown.

In 2006, Law and colleagues found that one of these DNA variations is associated with increased expression of a novel type of Neuregulin 1 called type 4 – one of the six known types of Neuregulin 1 proteins – in the brains of patients with schizophrenia.

The role of this protein in the brain is not completely understood but the other types of Neuregulin 1 proteins are involved in controlling how the brain develops and works in adults. In this study, Law and colleagues showed that Neuregulin 1 type 4 is specifically expressed in the brain – unlike the other types of Neuregulin 1. Also, the scientists showed that this protein is 3.5 times more abundant in fetal than adult brains, supporting the protein’s important role in the developing brain.

“Since the Neuregulin 1 protein plays a key role in brain development and is more abundant in fetal brains, DNA changes that alter the expression of this protein may contribute to schizophrenia by modifying the development and wiring of the brain,” Law says. “By understanding how this novel protein works in the brain, we may be able to target it in people with the disease.”

The researchers showed that the genetic change that causes overproduction of Neuregulin 1 type 4 is part of a DNA sequence called a promoter, which enables genes to be coded for proteins. A protein called a transcription factor binds to the promoter and helps other proteins to express the gene. When the promoter is altered, the transcription factor may not bind properly and impair genetic expression. Law and colleagues showed that alteration of the promoter in the genetic sequence linked to schizophrenia resulted in altered amounts of Neuregulin 1 type 4.

“For the first time, we have identified a promoter for the Neuregulin 1 gene and showed that the activity of that gene is altered by a single genetic variation in this promoter,” Law says. “These results will probably help us understand how DNA variations affect the function of this gene and lead to symptoms of schizophrenia.”

The researchers are now planning to investigate further the role of Neuregulin 1 type 4 in brain development and behavior and determine how various alterations of the Neuregulin 1 gene lead to schizophrenia.

“By better understanding the genetic causes of schizophrenia, we can start to make sense of the underlying biology of the disease and develop improved therapies based on people’s genes,” Law says. “The insight gained on the Neuregulin 1 gene is, I hope, bringing us closer to that goal.”

ARTICLE: “Molecular Cloning of a Brain-specific, Developmentally Regulated Neuregulin 1 (NRG1) Isoform and Identification of a Functional Promoter Variant Associated with Schizophrenia,” by Wei Tan, Yanhong Wang, Bert Gold, Jingshan Chen, Michael Dean, Paul J. Harrison, Daniel R. Weinberger, and Amanda J. Law

The American Society for Biochemistry and Molecular Biology is a nonprofit scientific and educational organization with over 11,900 members in the United States and internationally. Most members teach and conduct research at colleges and universities. Others conduct research in various government laboratories, nonprofit research institutions and industry. The Society’s student members attend undergraduate or graduate institutions.

Founded in 1906, the Society is based in Bethesda, Maryland, on the campus of the Federation of American Societies for Experimental Biology. The Society's purpose is to advance the science of biochemistry and molecular biology through publication of the Journal of Biological Chemistry, the Journal of Lipid Research, and Molecular and Cellular Proteomics, organization of scientific meetings, advocacy for funding of basic research and education, support of science education at all levels, and promoting the diversity of individuals entering the scientific work force.

Source: American Society for Biochemistry and Molecular Biology (ASBMB)

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.